Literature DB >> 34013553

The detailed clinical objectives approach to designing clinical trials and choosing estimands.

James Bell1, Alan Hamilton2, Oliver Sailer3, Florian Voss4.   

Abstract

Objective setting is a necessary early step in the development of a clinical trial. ICH E9(R1) notes that the clinical objectives of a trial lead directly to the choice of estimands but barely discusses objectives themselves. Indeed, there is very little guidance anywhere in literature about objectives in clinical trials. This article identifies the substantial overlap between description of estimands and high quality definitions of objectives. It consequently shows that the estimand is decided by the precise choice of trial objective, and that therefore estimand decisions should be made at the objective level. The Detailed Clinical Objectives approach is proposed to support this. It emphasises clarity, specificity and a clinical focus when choosing and documenting objectives. Template text and examples are included to provide guidance on how it can be used in real trials. Finally, we describe objective-driven trial design, emphasising how strong objective setting establishes an important foundation for rigorous trial design discussions, logistical and operational decision-making during trial preparations, and clear communication of results and conclusions at the end of the trial. Highlighting the distinctions between objectives and estimands, we note how an objective-based framework can build on the ICH E9(R1) estimand framework to address many of its unanswered questions.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  ICH E9(R1); estimands; objectives; trial design

Mesh:

Year:  2021        PMID: 34013553     DOI: 10.1002/pst.2129

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

1.  Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.

Authors:  C Fletcher; N Hefting; M Wright; J Bell; J Anzures-Cabrera; D Wright; H Lynggaard; A Schueler
Journal:  Ther Innov Regul Sci       Date:  2022-04-24       Impact factor: 1.337

2.  Principles and recommendations for incorporating estimands into clinical study protocol templates.

Authors:  Helle Lynggaard; James Bell; Christian Lösch; Amel Besseghir; Khadija Rantell; Volker Schoder; Vivian Lanius
Journal:  Trials       Date:  2022-08-19       Impact factor: 2.728

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.